Seaport's 4 Best Picks in Cannabis

This $12 billion industry could rise to around $630 billion over time, according to Seaport analysts.

How to Play This Apple Upgrade, and Semiconductor Strength: Market Recon

Consolidation is driving growth in the semis, but tech-led strength is never a bad thing.

Jim Cramer: Nvidia's Mellanox Deal, and Apple Upgrade, Have Lifted the Semis

It signals the glut in chips may be done with, which is good news for most of the semiconductor names.

Market Gyrations Send Shocking Reminders of 2009

Central banks around the world have caved in their desire to rid the world of the excess stimulus in the system that had been pumped in since the Global Financial Crisis.

YY Is Setting Up to Go Higher: Here's My Trading Game Plan

YY has been hammered time and time again after reporting earnings. Last week, that trend came to an end.

Defense Stocks May Have Bumpy Ride Amid Boeing News: Market Recon

After the Ethiopian Airlines crash, watch your Aerospace and Defense stocks.

Stocks Rattled By Growth, Trade Woes - Where Can Investors Find Value? Podcast

U.S. stocks closed out their worst week of the year Friday as investors shed risk around the world following a collapse in China exports, a sharp downgrade for European economic growth and a dismal reading for American job creation in the month of February.

Jim Cramer: The Global Rout Story

How did our stock market do during these endless global routs? Better than everyone else.

Get Ready for Global Weakness and Volatility: Market Recon

How Eurozone weakness and uncertainty on China trade are affecting the markets -- and how to prepare your portfolio.

Jim Cramer: No Room for Cynicism, JNJ's New Depression Drug Is Lifesaving

The approval of esketamine, known as Spravato, for use against severe depression is special -- it is saving lives.